Bristol Myers: positive data in kidney cancer

(CercleFinance.com) - Bristol Myers Squibb and Exelixis have announced positive results from the pivotal phase III "CheckMate -9ER" trial evaluating Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in previously untreated advanced renal cell carcinoma.


The study achieved its primary endpoint of significantly improving progression-free survival, as well as its secondary objectives of overall survival and the objective response rate, compared to sunitinib, while demonstrating a favourable safety profile.


Copyright (c) 2020 CercleFinance.com. All rights reserved.